Genematrix
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genematrix develops diagnostic test kits that detect infectious diseases, including sexually transmitted infections, tuberculosis, human papillomavirus, respiratory infections, and acute gastroenteritis, by analysing genetic material from a patient sample.
Its products are used in clinical and laboratory settings, and it also has vaccine and cancer-immunotherapy programmes in development. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core commercial business centres on its NeoPlex product line, which can test for multiple pathogens simultaneously in a single run using proprietary molecular-detection technologies it has developed in-house.
Summary is AI-generated and may contain errors · figures from DART filings
Genematrix in five facts
What does Genematrix do?
Genematrix develops diagnostic test kits that detect infectious diseases, including sexually transmitted infections, tuberculosis, human papillomavirus, respiratory infections, and acute gastroenteritis, by analysing genetic material from a patient sample.
Where is Genematrix listed and in which sector?
Genematrix (Korean name: 진매트릭스) trades under KRX code 109820 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Genematrix?
Its market capitalisation was US$23.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genematrix's latest annual revenue and operating profit?
For fiscal year 2025, Genematrix reported revenue of US$8M, an operating loss of US$512.6K and a net loss of US$1.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 6.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.